The Center for Biosimilars’ Post

Freedom Rings for Patients With nAMD! 🎆This Independence Day we're celebrating more than just fireworks! Formycon's Ahzantive (aflibercept-mrbb) just became the third biosimilar approved by the FDA to treat eye conditions! What's the big deal? Well, head over to the link to learn how Ahzantive stacks up against the competition. https://lnkd.in/eaUfP7SQ

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics